Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Orticumab - Abcentra

Drug Profile

Orticumab - Abcentra

Alternative Names: 2D03; Anti-oxLDL; BI-204; MLDL 1278A; RG 7418

Latest Information Update: 07 Feb 2019

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator BioInvent International
  • Developer Abcentra; BioInvent International; Genentech
  • Class Anti-inflammatories; Antibodies; Antihyperlipidaemics; Monoclonal antibodies
  • Mechanism of Action Oxidised low density lipoprotein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Clinical Phase Unknown Atherosclerosis; Psoriasis

Most Recent Events

  • 07 Feb 2019 Abcentra plans phase II trials for Psoriasis and Atherosclerosis
  • 30 Jan 2019 CardioVax is now called Abcentra
  • 30 Jan 2019 Clinical trials in Atherosclerosis, Psoriasis (Parenteral), prior to January 2019
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top